Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that.
An honest uncertainty about retatrutide dose escalation rather than a disguised assertion.
I do not know the answer and I have not been able to find one. What I have is the shape of the question, which may be worth more than my guess at the answer.
I have three months of notes on retatrutide dose escalation and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Thank you for taking the time. That was more work than a reply usually is.
Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I had written a reply contradicting post #6 and deleted it. Here is what survived.
Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not match what someone self-prescribing would choose.
Stating my assumptions rather than smuggling them in.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.
Worth reading the earlier posts in this thread before acting on mine.
Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes.
It cost nothing to check and would have cost something not to.
Adding the measurement that post #9 says would settle it.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
Two sources, same conclusion, and I could not rule out that one copied the other.
Filing a mild objection to the consensus on retatrutide dose escalation. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
What I would check first on retatrutide dose escalation is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Right — I had this wrong and I am glad to have read it before it mattered.
The arithmetic in post #13 is right; the assumption feeding it is the part to check.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
Reading it back, the second half matters more than the first.
Practical experience of retatrutide dose escalation, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
This is the sort of thing that ought to be settled and apparently is not.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
For what it is worth, the same held on the two occasions I checked.
I think the retatrutide dose escalation question is answerable and has not been answered, which is a more optimistic position than most of this thread.
That is consistent with mine, for whatever one more account is worth.
Confirming post #21 from a second method, which matters more than confirming it from a second person.
Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.
I would be glad to be shown a cleaner way of putting this.
I had written a reply contradicting post #20 and deleted it. Here is what survived.
On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.
A single observation, in a thread that deserves better than single observations.
Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.
That is the honest state of it as of this week.
Answering the question post #24 raises rather than the one it answers.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I checked the source rather than the summary, and they differ.
Post #26 is the version of this I will quote in future. One addition.
The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Worth separating two things that post #28 runs together.
How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population.